The growing recognition of gut-immune system communication reveals how disrupted intestinal bacteria may drive allergic diseases that affect millions worldwide. Understanding this connection could transform treatment approaches for conditions like asthma and food allergies by targeting the digestive system rather than just managing symptoms. This comprehensive analysis of small intestinal bacterial overgrowth (SIBO) prevalence across allergic conditions reveals striking patterns. Among bronchial asthma patients, bacterial overgrowth occurs in 60-100% of cases, while food allergy sufferers show 50-87.5% prevalence. Mast cell activation syndrome patients exhibit 30.9% rates, and chronic spontaneous urticaria affects 27.9%. Diagnosis relied on standardized lactulose or glucose breath tests measuring bacterial fermentation byproducts. The proposed mechanism involves bacterial overgrowth triggering Th2 immune responses through mucosal pathways and low-grade endotoxemia, ultimately increasing production of key allergic mediators including interleukins IL-4, IL-5, and IL-13. This gut-allergy axis represents an emerging frontier in immunology that challenges traditional allergy treatment paradigms. The extremely high SIBO prevalence in asthma patients suggests causation rather than mere correlation, though the cross-sectional study design limits definitive conclusions. Treatment outcomes varied significantly by condition—SIBO therapy improved asthma and mast cell syndrome symptoms but showed minimal benefit for urticaria, indicating disease-specific mechanisms. The concept builds on established microbiome research but extends it to specific bacterial overgrowth patterns. While promising for personalized medicine approaches, these findings require validation through randomized controlled trials before clinical implementation. The research limitations include small sample sizes and heterogeneous diagnostic criteria across studies, making effect size calculations preliminary.